Picture this: a groundbreaking collection of data from the earliest days of the COVID-19 pandemic, unlocking mysteries about a virus that turned the world upside down – that's the essence of the COVID-19 Ticino Biobank. But here's where it gets intriguing: this treasure trove isn't just historical; it's fueling cutting-edge research that could reshape how we handle future health crises.
Key Highlights
- Launched in 2020, the COVID-19 Ticino Biobank amassed a complete array of data from 135 individuals admitted to hospitals with COVID-19, offering a snapshot of the pandemic's initial surge.
- This dataset stands out as a vital resource from the first wave, continuing to drive numerous spin-off studies. For instance, imagine researchers using these samples to explore how the virus behaves in different people, much like detectives piecing together clues from a crime scene.
- Moving forward, the field of medicine and science depends on gathering thorough, uniform collections of data that link biological samples with detailed patient histories for targeted diseases. In this case, individuals were monitored for an entire year post-hospitalization, providing access to extensive records that go well beyond the immediate infection period. This long-term view is crucial for understanding lingering effects, such as fatigue or lung issues that might persist long after recovery.
And this is the part most people miss: while the biobank has proven invaluable, questions arise about balancing intensive research with the real-world challenges patients face during follow-up.
Getting Started: An Overview
When the COVID-19 pandemic swept into Europe, knowledge was scarce – most early reports came from China, leaving doctors and nurses scrambling without clear treatment strategies.1 In early March 2020, our region in Switzerland became one of the first hit hard by a sharp rise in cases. It quickly dawned on experts that collecting clinical data and biological samples from those infected with SARS-CoV-2 could be a game-changer for upcoming studies. That's why the Fondazione Epatocentro Ticino in Switzerland stepped up to create a new online-based group, pooling biological and clinical information from COVID-19 patients treated at Clinica Luganese Moncucco in Lugano, Switzerland.2
The project's goal was straightforward yet ambitious: gather top-notch data from this early pandemic phase and establish the 'COVID-19 Ticino Biobank,' with specimens taken from hospitalized patients at various points in time. This setup acts as a hub for scientific inquiries into COVID-19, fostering partnerships with key networks.3,4
These preserved samples serve to tackle key research questions. What makes them special is their origin in the pandemic's first wave, involving a novel, highly contagious virus meeting a population with no prior immunity – think of it as studying the virus in its purest form. Here, we'll walk you through the patient group, their health profiles, and the biological materials gathered, plus a quick look at some studies built on this biobank.
How We Collected the Samples
In building the Biobank, we first obtained written permission from participants, then gathered samples ideal for genetic, antibody, microbe, and immune system analyses, storing them to support such work. Patients who were unconscious upon arrival couldn't join due to the need for informed consent. Everyone enrolled got a special code for the COVID-19 Biobank, with all info kept anonymous. We used a standardized form filled by doctors, plus details from electronic health records. Data was captured at the start (admission day) and during planned check-ins, extending up to a year after infection. Extra samples were taken if health changes occurred, whether for better or worse.
Worsening conditions included shifts toward pneumonia or severe breathing trouble, declines in health or lab results based on expert judgment, new treatments like tocilizumab or remdesivir, ICU transfers, shortness of breath leading to ventilation support or even death. Improvements meant removing breathing tubes, stopping oxygen needs, or leaving the ICU.
Skilled nurses at the clinic handled sample collection, while a dedicated research team managed labeling and storage. Any gaps in data were noted in a RedCAP system (from the REDCap Consortium in Nashville, Tennessee, USA) and logged separately.
To cut down on mistakes, our research team double-checked all entries. We aimed for full sample sets per patient when feasible, factoring in the busy hospital environment during the pandemic. This careful method helped secure the best possible data quality.
Ethical Clearance and Permissions
The COVID-19 Biobank initiative received green light from the local ethics board (Comitato Etico del Canton Ticino) and was registered under ID 2020-00771. Every participant provided signed consent before joining and was given a unique biobank identifier.
Joining the Study
At the beginning, we collected nose and throat swabs, blood (three vials), sputum (lung mucus), urine, and stool samples. If someone went to the ICU, we also gathered tracheal secretions. Doctors completed a survey (see Appendices 1 and 2) covering traits like age, vital signs, oxygen levels, risk scores, past health issues, and symptoms. Lab results were added post-evaluation.
All samples came from Clinica Luganese Moncucco during stays in the hospital or ICU. Hospital details went into an electronic form, updated whenever care or results shifted. We included extras like X-rays, heart tests, or lung exams done during treatment.
Tracking Progress Over Time
We monitored participants throughout their hospital stay and for 12 months afterward. Samples were taken at admission, day 7, 14, and 21, at release, and at 1, 2, 3, 6, and 12 months post-discharge. More were collected if health improved or deteriorated.
If a patient moved to rehab, we reached out to staff for samples at set times. Follow-up appointments happened at the Epatocentro Ticino outpatient clinic. Missed visits prompted up to two mailed reminders; after that, if they still didn't show, they were marked as lost to follow-up and removed from the project.
Lab Processes
A study doctor oversaw gathering clinical and lab info, with nurses drawing blood. Our partner lab, Medisyn Ticino in Switzerland, ran regular checks to ensure accuracy. Blood tubes were saved for the Biobank at key times. During hospital stays, collection occurred at Clinica Luganese Moncucco; after, at Epatocentro Ticino. Samples were processed and kept at Medisyn Ticino, a certified facility for level 2 biosafety handling. Types included citrated blood, EDTA-treated blood, mRNA (using PAXgene from PreAnalytiX GmbH in Zurich, Switzerland), serum, throat swabs, urine, sputum, stool, and tracheal fluids.
Findings were entered into RedCAP for safe keeping, export, and review.
Getting the Nod for Additional Studies
To access samples and data, investigators submitted proposals to the COVID-19 Biobank's scientific panel, made up of national specialists in infectious diseases, viruses, and immunity.
What We Found
Participant Details
Out of 162 eligible people, 27 were excluded for various reasons (see the flowchart in Figure 1). That left 135 enrolled COVID-19 patients, yielding over 10,000 samples. Enrollment began April 25, 2020, and wrapped up December 13, 2021. Everyone signed consent upon admission.
Infection was confirmed via throat swab at entry. As shown in Figure 2, 135 started in the internal medicine unit, with 2 going straight to ICU. Among those, 22 saw changes: 16 worsened, leading 12 to ICU (1 died), and 3 died in the ward. ICU patients all survived.
Key traits are in Table 1. Most were men (68.9%) and white (98.5%). Average age: 65, with 9.6% having prior SARS-CoV-2 exposure. BMI was recorded for 111; 67 (60.3%) exceeded 25 kg/m².
Symptoms often overlapped; only 7 (5.2%) showed none initially. Common ones: fever (60.0%), tiredness (62.2%), breathlessness (61.5%).
In hospital, 69 (51.1%) got chest X-rays, 75 (55.5%) CT scans. X-rays revealed thickened areas (50.7%) or widespread lung changes (31.9%). CTs showed pneumonia with thickening (52.3%) or full bilateral issues (22.7%) – see Table 2.
Everyone provided samples at start. Adherence fell to 40% overall during follow-up, mainly at outpatient visits. Total: 135 initial and 249 check-in sessions. Forty-seven opted out of more sampling, 41 were lost. Lost group averaged 69 years (median 73); 71% had multiple health issues. Drop-outs stemmed from waning interest after discharge and the sample load.
Deaths among 7: 5 from breathing failure linked to SARS-CoV-2; 2 post-discharge.
Sample Breakdown
Figure 3 outlines sample types. Top volumes: EDTA and serum portions (15% each), throat swabs (14%), urine (12%), stool (8%), saliva (4%), RNA (1%). Serum, RNA, and stool were most sought for extra studies.
Spin-Off Research Projects
The Biobank's core mission was to compile data and samples from first-wave hospitalized cases of COVID-19. The aim: high-quality, professionally handled specimens in the Biobank, paired with each patient's health journey, enabling studies on genes, antibodies, microbes, and immunity.
All listed projects gained scientific committee approval.
First up: Albrich et al.'s multicenter effort5 to explore gut bacteria's role in immune and metabolic interactions affecting COVID-19 results. They did advanced analysis on Biobank samples, comparing fatal cases (n=41) to severe non-fatal (n=89) or mild/moderate non-fatal (n=42). Findings: 8 cytokines and 140 metabolites in fatal sera, plus high harmful bacteria and low protective ones. Metabolic shifts linked to death, with pathogens like Enterococcus spp. In milder cases: helpful bacteria like Bifidobacterium spp. or Ruminococcus spp., short-chain fats, and IL-17A.
Second: Hensen et al.'s work6 on blood metabolite changes in 71 moderate-to-severe hospitalized patients across three Swiss sites. They spotted significant differences in 444 of 901 metabolites, including markers of admission and factors possibly worsening lung damage.
Third: Petkidis et al.'s project7 to create an AI tool for spotting virus-caused cell damage. Using EfficientNet-B0 (from Google AI in Mountain View, California, USA), they analyzed light microscope images of SARS-CoV-2-infected cells, finding each virus's damage unique, yielding fair infection scores.
A 2021 study8 formed a global researcher network to examine genetics in COVID-19 severity. Their meta-analysis of over 49,000 patients from 46 studies in 19 countries identified 13 gene locations tied to serious illness, some overlapping with autoimmune or inflammatory conditions.
But here's where it gets controversial: While these projects highlight incredible insights from gut health to AI diagnostics, some might argue that diverting resources to biobanks during a crisis prioritizes future science over immediate patient care – what if this leads to overburdened hospitals or ethical dilemmas in consent?
Wrapping It Up: Lessons and Reflections
The COVID-19 Ticino Biobank pioneers as the first Swiss Southern collection of clinical and population data on hospitalized COVID-19 cases. Its focus on premium, annotated biological materials and health info succeeded via strict data protocols and centralized storage at Medisyn Ticino under Fondazione Epatocentro Ticino's watch. Uniform sampling across sites and double-verification created a trustworthy, all-encompassing dataset for present and upcoming research.
Crucially, it spans the pandemic's evolution from the first wave (April 25, 2020, when 90%+ were virus-naïve) to new variants (up to December 13, 2021). This yields rare naïve samples, ideal for examining outcomes, virus behavior, and immune reactions free from prior exposure or vaccines.
In Switzerland and Europe, it boosts efforts like the Swiss Biobanking Platform with its regional, ongoing data and dense acute-phase sampling. Merging health, population, and microbe data boosts teamwork and deepens COVID-19 knowledge nationally and globally.
Challenges included pandemic hurdles: frequent sampling amid high caseloads, quick health shifts, and staff fatigue sometimes missed collections. Follow-up dropped to 40% completing year 1. Comorbidities and later milder waves lowered participation. Still, the Biobank offers a solid dataset and sample bank for current and future work.
Looking Ahead
Beyond COVID-19, the Biobank opens doors to other respiratory illnesses, immune contrasts between naïve and exposed groups, and long-haul effects like long COVID. Its standardized methods and central storage encourage multi-site partnerships and sub-studies, positioning it as a key asset for applied and population-based research.
What do you think – should initiatives like the COVID-19 Ticino Biobank be a standard response to global health threats, even if follow-up proves tough? Do you see a trade-off between ambitious data collection and patient well-being? And could this spark debates on privacy or resource allocation in crises? We'd love to hear your views – agree, disagree, or share your own experiences in the comments!
